We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics
News

Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics

Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics
News

Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Catalyst Biosciences, Inc. has announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases.

Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments totaling up to $195 million, exclusive of royalty payments, for the development of drug candidates against two distinct targets.

Through the collaboration, MedImmune will support the discovery research and preclinical development by Catalyst of Alterase™ therapeutics against an undisclosed target, with an option to expand the agreement to include a second target.

Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins. MedImmune will be responsible for all development, manufacturing, and commercialization efforts associated with the products discovered through the collaboration in exchange for future milestones and royalties.

"We are very pleased to add MedImmune, a leading developer of biologic therapies, as a partner," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Our Alterase drug discovery engine is creating novel next-generation protein therapeutics against a broad variety of important disease targets. Collaborations such as this demonstrate the high value of our discovery and protein engineering capabilities."
Advertisement